MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx® and NexoBrid®. EscharEx® is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid®, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.